Paclitaxel, a natural product isolated from the bark of the Pacific yew, is effective in treating refractory metastatic ovarian cancer.  Unlike any other antineoplastic agents, paclitaxel appears to have several possible mechanisms of action, including an antimicrotubule action through the promotion of tubulin polymerization and stabilization of microtubules, thereby, halting mitosis and promoting cell death.

CHEMICAL PROPERTIES

SAFETY INFORMATION

PRODUCT USAGE

Paclitaxel is a potent antineoplastic agent originally derived from the Pacific yew tree, widely regarded as a cornerstone in clinical oncology. Its primary application is the treatment of various malignancies, including breast, ovarian, and non-small cell lung cancers, by stabilizing microtubules and inhibiting cell division. In the pharmaceutical industry, it is formulated into sophisticated drug delivery systems, such as albumin-bound particles (nab-paclitaxel), to enhance solubility and reduce side effects. Beyond systemic chemotherapy, Paclitaxel is extensively used in the medical device sector, specifically as a coating for drug-eluting stents and balloons to prevent restenosis in cardiovascular procedures. Its critical role extends to biomedical research, where it serves as a fundamental tool for studying cytoskeleton dynamics and developing next-generation targeted cancer therapies.